Valvular & structural heart disease
Antithrombotic therapy following transcatheter aortic valve implantation: a Danish nationwide study
Authors' conclusion
Antithrombotic therapy patterns post-TAVI have changed over the first 14 years of TAVI in Denmark. Use of DAPT and OAC+ decreased with a concomitant increase in SAPT and OAC.
Study context
- Population
- Danish patients with aortic stenosis who underwent first-time TAVI from 2008 to 2021patients undergoing TAVI · without atrial fibrillation (AF) 3,975 · AF patients 2,472
- Participants
- 6,447 patients
- Exposure
- Trends in use of antithrombotic therapy post-TAVI, by AF status
- Outcome
- Antithrombotic therapy received, by AF status
Methodological detailsDanish registries
- Danish registries
Main finding
As reported in the abstract
- Among patients without AF, most patients received single antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT)
- In AF patients, most patients received OAC or OAC+
Observational data: associations, not effects.
Further findings
Trend in antithrombotic therapy, patients without AF · first 14 years of TAVI
- SAPT increased
- from 15.6% to 69.5%
- DAPT decreased
- from 56.3% to 9.1%
Trend in antithrombotic therapy, AF patients · first 14 years of TAVI
- OAC increased
- from 13.0% to 77.9%
- OAC+ decreased
- to 9.1%
Persistence and changes in treatment among survivors · 15 months
- Most patients without AF either remained with or shifted to SAPT
- AF patients either remained in or shifted to the OAC group
Original publication
Antithrombotic therapy following transcatheter aortic valve implantation: a Danish nationwide study. Eur Heart J Qual Care Clin Outcomes. Published 31 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →